moderate - Hospital capital equipment budgets are somewhat insulated by healthcare demand fundamentals and multi-year planning cycles, but discretionary cancer center expansions and system upgrades are deferred during economic downturns. Government healthcare spending and private hospital system financial health directly impact purchasing decisions. The 2-3 year sales cycle creates lag effects between economic conditions and revenue realization.

Rising rates negatively impact Accuray through multiple channels: (1) higher financing costs on the company's $300M+ debt burden compress already thin margins, (2) hospital customers face increased borrowing costs for capital equipment purchases, reducing order volumes, (3) valuation multiples contract for unprofitable growth companies as risk-free rates rise. The company's negative FCF and refinancing needs make it particularly vulnerable to rate increases.

value/turnaround - The stock attracts distressed/special situations investors betting on operational improvement, debt restructuring, or acquisition by a larger strategic buyer. The 76% one-year decline and sub-0.2x P/S ratio suggest deep value positioning, but high volatility and execution risk deter institutional quality investors. Momentum investors have exited given negative price trends.